Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Nivolumab (Opdivo) for classical Hodgkin Lymphoma
(Notification to Implement Issued as of May 18, 2018)

Osimertinib (Tagrisso) for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (first line)
(Open for Input on Submission until May 31, 2018)

Lenvatinib (Lenvima) for Advanced Renal Cell Carcinoma
(Pending Submission as of May 9, 2018)

Lutetium Lu 177 dotatate (Lutathera) for Gastroenteropancreatic Neuroendocrine Tumors
(Pending Submission as of May 9, 2018)

Pralatrexate (Folotyn) for Peripheral T-Cell Lymphoma
(Pending Submission as of May 1, 2018)



Find a Drug Review